At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Panobinostatdrug
Likely dose
Panobinostat 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Multi-center Single Agent Panobinostat Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Panobinostat Study and Are Judged by the Investigator to Benefit From Continued Single Agent Panobinostat Treatment
In Brief
A Phase 2 clinical trial evaluating Panobinostat for Hematologic Neoplasms. Completed, enrolled 9 participants across 7 sites in 4 countries.
Detailed Summary
The study allowed continued use of single agent panobinostat in patients who were on single agent panobinostat treatment in a Novartis-sponsored study which had met its endpoint and were benefiting from the treatment as judged by the investigator.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Neoplasms
CountriesIsrael, Netherlands, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartJun 2013
Primary CompletionNov 2018
TodayJul 2026
First PostedMar 4, 2013
Enrollment StartJun 24, 2013
Primary CompletionNov 19, 2018
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 13.3 years ago
Interventions
Panobinostatdrug
Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.